Total Payments
$596,543
2024 Payments
$85,599
Companies
50
Transactions
1,593
Medicare Patients
23,648
Medicare Billing
$3.1M
Payment Breakdown by Category
Other$446,689 (74.9%)
Consulting$68,723 (11.5%)
Food & Beverage$41,981 (7.0%)
Travel$37,162 (6.2%)
Research$1,732 (0.3%)
Education$211.43 (0.0%)
Gifts$45.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $322,705 | 129 | 54.1% |
| Consulting Fee | $68,723 | 41 | 11.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $68,088 | 24 | 11.4% |
| Food and Beverage | $41,981 | 1,206 | 7.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $37,900 | 14 | 6.4% |
| Travel and Lodging | $37,162 | 157 | 6.2% |
| Honoraria | $17,997 | 12 | 3.0% |
| Unspecified | $1,732 | 5 | 0.3% |
| Education | $211.43 | 4 | 0.0% |
| Gift | $45.00 | 1 | 0.0% |
Payments by Type
General
$594,811
1,588 transactions
Research
$1,732
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $166,042 | 316 | $0 (2022) |
| ABBVIE INC. | $160,734 | 219 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $95,034 | 156 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $31,800 | 44 | $0 (2017) |
| Shire North American Group Inc | $22,748 | 59 | $0 (2019) |
| BIOTISSUE HOLDINGS INC. | $16,431 | 97 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $16,038 | 44 | $0 (2021) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $14,650 | 100 | $0 (2024) |
| Ocular Therapeutix, Inc. | $11,522 | 44 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $11,256 | 49 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $85,599 | 271 | Bausch & Lomb Americas Inc. ($50,547) |
| 2023 | $124,869 | 287 | ABBVIE INC. ($72,898) |
| 2022 | $166,672 | 345 | ABBVIE INC. ($73,178) |
| 2021 | $89,652 | 222 | Allergan, Inc. ($67,651) |
| 2020 | $13,017 | 107 | Allergan, Inc. ($9,042) |
| 2019 | $34,976 | 135 | Bausch & Lomb, a division of Bausch Health US, LLC ($13,568) |
| 2018 | $17,678 | 76 | Allergan Inc. ($12,384) |
| 2017 | $64,080 | 150 | Valeant Pharmaceuticals North America LLC ($31,800) |
All Payment Transactions
1,593 individual payment records from CMS Open Payments — Page 1 of 64
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Dompe US, Inc. | OXERVATE (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: SOLUTION/ DROPS | ||||||
| 12/23/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | Cash or cash equivalent | $20.14 | General |
| 12/23/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | Cash or cash equivalent | $1.62 | General |
| 12/20/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 12/19/2024 | ABBVIE INC. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: EYE CARE | ||||||
| 12/18/2024 | Alcon Vision LLC | Clareon (Device) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: Ophthalmology | ||||||
| 12/18/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $10.00 | General |
| Category: Ophthalmology | ||||||
| 12/18/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug), MIEBO | Food and Beverage | In-kind items and services | $4.20 | General |
| Category: Ophthalmology | ||||||
| 12/17/2024 | ABBVIE INC. | DURYSTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: EYE CARE | ||||||
| 12/17/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | In-kind items and services | $4.65 | General |
| 12/15/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | In-kind items and services | $21.58 | General |
| 12/13/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: Dry eyes | ||||||
| 12/12/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: EYE CARE | ||||||
| 12/11/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/09/2024 | Dompe US, Inc. | OXERVATE (Drug) | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: SOLUTION/ DROPS | ||||||
| 12/05/2024 | ABBVIE INC. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $8.15 | General |
| Category: EYE CARE | ||||||
| 12/04/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 12/04/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $11.92 | General |
| Category: Ophthalmology | ||||||
| 12/04/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $1.49 | General |
| Category: Ophthalmology | ||||||
| 12/03/2024 | Alcon Vision LLC | Clareon (Device) | Food and Beverage | In-kind items and services | $27.60 | General |
| Category: Ophthalmology | ||||||
| 12/02/2024 | Dompe US, Inc. | OXERVATE (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: SOLUTION/ DROPS | ||||||
| 11/26/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Ophthalmology | ||||||
| 11/25/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | Cash or cash equivalent | $196.97 | General |
| 11/21/2024 | ABBVIE INC. | DURYSTA (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: EYE CARE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle- Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a new formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution at two different Concentrations in patients with Dry Eye Disease (REDUCO) | Dompe Farmaceutici S.p.A. | $1,732 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 6,255 | 10,122 | $3.2M | $858,468 |
| 2022 | 29 | 6,258 | 10,399 | $3.0M | $792,391 |
| 2021 | 27 | 6,059 | 10,512 | $3.1M | $842,982 |
| 2020 | 23 | 5,076 | 8,333 | $2.3M | $625,837 |
Total Patients
23,648
Total Services
39,366
Medicare Billing
$3.1M
Procedure Codes
109
All Medicare Procedures & Services
109 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 65778 | Placement of amniotic membrane on eye surface for wound healing | Office | 2023 | 71 | 137 | $342,500 | $167,772 | 49.0% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 937 | 2,040 | $510,000 | $146,796 | 28.8% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 794 | 801 | $240,300 | $81,348 | 33.9% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2023 | 114 | 189 | $472,500 | $81,334 | 17.2% |
| J7351 | Injection, bimatoprost, intracameral implant, 1 microgram | Office | 2023 | 20 | 370 | $92,500 | $57,237 | 61.9% |
| 83861 | Microfluid analysis of tears | Office | 2023 | 549 | 2,030 | $101,500 | $44,644 | 44.0% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2023 | 81 | 133 | $119,700 | $38,823 | 32.4% |
| 92250 | Photography of the retina | Office | 2023 | 936 | 1,182 | $354,550 | $36,409 | 10.3% |
| 95930 | Measurement of nerve conduction using visual stimulation testing with report | Office | 2023 | 386 | 404 | $80,800 | $22,847 | 28.3% |
| 65855 | Laser repair to improve eye fluid flow | Office | 2023 | 52 | 102 | $153,000 | $21,473 | 14.0% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 416 | 436 | $87,300 | $21,232 | 24.3% |
| 65820 | Incision to improve eye fluid flow | Facility | 2023 | 13 | 20 | $20,000 | $14,700 | 73.5% |
| 92273 | Measurement of retinal and optic nerve function | Office | 2023 | 114 | 119 | $35,700 | $13,368 | 37.4% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 548 | 556 | $111,200 | $12,675 | 11.4% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 106 | 106 | $31,800 | $11,992 | 37.7% |
| 92133 | Imaging of optic nerve | Office | 2023 | 421 | 438 | $87,600 | $11,950 | 13.6% |
| 66982 | Complex removal of cataract with insertion of prosthetic lens | Facility | 2023 | 14 | 16 | $41,600 | $10,082 | 24.2% |
| 68115 | Removal of growth of eyelid lining, more than 1.0 cm | Office | 2023 | 12 | 24 | $24,000 | $9,573 | 39.9% |
| 66174 | Dilation of fluid outflow drainage within eye | Facility | 2023 | 11 | 17 | $25,500 | $9,337 | 36.6% |
| 66761 | Creation of eye fluid drainage tracts in iris using a laser, per session | Office | 2023 | 16 | 31 | $46,500 | $8,307 | 17.9% |
| 92134 | Imaging of retina | Office | 2023 | 176 | 227 | $45,400 | $7,703 | 17.0% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 28 | 131 | $45,850 | $7,454 | 16.3% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 145 | 218 | $54,500 | $6,939 | 12.7% |
| 66030 | Injection of medication into eye | Office | 2023 | 19 | 35 | $17,500 | $5,232 | 29.9% |
| 67840 | Removal of growth of eyelid | Office | 2023 | 14 | 14 | $8,400 | $3,575 | 42.6% |
About Dr. Eric Mann, MD
Dr. Eric Mann, MD is a Ophthalmology healthcare provider based in Dover, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/11/2005. The National Provider Identifier (NPI) number assigned to this provider is 1508847930.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Mann, MD has received a total of $596,543 in payments from pharmaceutical and medical device companies, with $85,599 received in 2024. These payments were reported across 1,593 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($322,705).
As a Medicare-enrolled provider, Mann has provided services to 23,648 Medicare beneficiaries, totaling 39,366 services with total Medicare billing of $3.1M. Data is available for 4 years (2020–2023), covering 109 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Dover, NJ
- Active Since 11/11/2005
- Last Updated 07/08/2007
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1508847930
Products in Payments
- DURYSTA (Drug) $218,924
- MIEBO (Drug) $66,107
- VUITY (Drug) $43,982
- RESTASIS (Drug) $27,480
- XIIDRA (Drug) $25,443
- LOTEMAX SM (Drug) $13,574
- Cequa (Drug) $11,745
- RESTASIS MULTIDOSE (Drug) $11,721
- PROLENSA (Drug) $11,674
- ACTHAR (Biological) $11,606
- DEXTENZA (Drug) $11,522
- rhopressa (Drug) $8,931
- LOTEMAX GEL (Drug) $8,565
- ALREX (Drug) $6,971
- ZYLET (Drug) $6,970
- PAZEO (Drug) $5,162
- enVista MX60 IOL (Device) $4,342
- Clareon (Device) $4,140
- AMINOGRAFT (Medical Supply) $4,013
- LUMIGAN (Drug) $3,541
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Dover
Dr. David Creech, Md, MD
Ophthalmology — Payments: $28,228
Ophthalmology $28,228
David Lu, Md, MD
Ophthalmology — Payments: $4,797
Ophthalmology $4,797
Dr. Timothy Doyle, D.o, D.O
Ophthalmology — Payments: $3,787
Ophthalmology $3,787
Asma Saud
Ophthalmology — Payments: $1,827
Ophthalmology $1,827
Dr. Thomas Perkowski, D.o, D.O
Ophthalmology — Payments: $195.48
Ophthalmology $195.48
Dr. Andrew Wherley, Md, MD
Ophthalmology — Payments: $176.39
Ophthalmology $176.39